Ci­pla, Uni­taid join hands to re­duce HIV drug price

BioSpectrum (Asia) - - Company News -

Ci­pla and Uni­taid have inked a pact to lower the price of the first com­bi­na­tion ther­apy (con­tain­ing co-tri­mox­a­zole, iso­ni­azid and vi­ta­min B6) that pre­vents op­por­tunis­tic in­fec­tions in peo­ple liv­ing with HIV. Un­der this agree­ment, In­dian firm Ci­pla will re­duce the ceil­ing price of the medicine by more than 30 per cent from $ 3 to $ 1.99 per per­son, per month, for all pub­lic-sec­tor pro­cur­ers in low and mid­dle-in­come coun­tries.

The price of the prod­uct is ex­pected to come down more as gov­ern­ments and in­ter­na­tional fund­ing bod­ies pro­cure larger quan­ti­ties for their HIV treat­ment pro­grammes. The com­bi­na­tion ther­apy is a once-daily pill that pro­tects in three ways against TB, the lead­ing cause of death among peo­ple with HIV, and against other life-threat­en­ing bac­te­rial, and pro­to­zoan in­fec­tions.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.